A Pilot Study to Correlate 4-18F- Fluoro-1-naphthol 18F-4FN PET/CT Imaging With Chronic Graft Versus Host Disease Manifestations

Part of paid clinical trials in Houston, Texas.

Sponsor
M.D. Anderson Cancer Center
Study ID
NCT07325253
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Host Disease Manifestation
  • PET/CT Imaging
  • Pilot Study

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • [18F]-4FN — DRUG
    Given by IV
  • PET-CT — OTHER
    Imaging

Study Details

To study the safety and possible side effects of using the imaging agent 4-\[18F\]Fluoro-1-Naphthol (also called \[18F\]4FN) in PET/CT scans for participants with chronic GVHD.

Key Dates

Start date
Nov 18, 2025
Status verified
Jun 2026
Primary completion
Jan 3, 2028
Completion
Jan 3, 2030

Study Design

Enrollment
16 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC

Arms

  • Experimental: Part 1
    Prognostic Biomarker Analysis - \[18F\]4FN PET/CT at Baseline
  • Experimental: Part 2
    Predictive/PD Biomarker Analysis - \[18F\]4FN PET/CT before a New Systemic Therapy

Primary Outcome Measure

Safety and adverse events (AEs). [ Time Frame: Through study completion; an average of 1 year. ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
MD Anderson Cancer CenterHoustonTexas77030
George L Chen, MD
[email protected]
713-792-3630
George L Chen, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Houston, TX

By research site
MD Anderson Cancer Center· Houston, TX

Related Studies